Related Experiment Video
Updated: Dec 9, 2025
04:22
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.2K
Correction to: Deciphering cellular transcriptional alterations in Alzheimer's disease brains
Xue Wang1, Mariet Allen2, Shaoyu Li3
1Department of Health Sciences Research, Mayo Clinic Florida, Jacksonville, FL, USA. Wang.Xue@mayo.edu.
Molecular Neurodegeneration
|September 15, 2020
Abstract:
An amendment to this paper has been published and can be accessed via the original article.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
01:22Alzheimer's Disease: Treatment
635
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
635